CTOs on the Move

Mammoth Biosciences

www.mammoth.bio

 
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mammoth.bio
  • 1000 Marina Boulevard Suite 600
    Brisbane, CA USA 94005
  • Phone: 650.294.8583

Executives

Name Title Contact Details
Janice Chen
 Co-Founder and Chief Technology Officer Profile

Funding

Mammoth Biosciences raised $23M on 07/31/2018
Mammoth Biosciences raised $45M on 01/30/2020

Similar Companies

Wichita Radiological Group, P.A.

Wichita Radiological Group, P.A. is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Foxtag Enterprises

Foxtag Enterprises is a Rockledge, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GFI LAB

GFI LAB is a Rockwood, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SimQuest

SimQuest is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.